|
시장보고서
상품코드
2091403
신경학 분야 임상시험 시장 규모, 점유율, 성장 분석 : 단계별, 연구 디자인별, 적응증별, 스폰서별, 지역별 - 업계 예측(2026-2033년)Neurology Clinical Trials Market Size, Share, and Growth Analysis, By Phase (Phase I, Phase II), By Study Design (Interventional Studies, Observational Studies), By Indication, By Sponsor, By Region - Industry Forecast 2026-2033 |
||||||
세계의 신경학 임상시험 시장 규모는 2024년에 52억 2,000만 달러로 평가되었으며, 2025년 55억 5,000만 달러에서 2033년까지 91억 1,000만 달러로 확대되어 예측 기간(2026-2033년) 동안 CAGR 6.39%로 성장할 것으로 전망됩니다.
세계 신경학 임상시험 시장은 알츠하이머병이나 파킨슨병 등 신경퇴행성 질환의 발병률 증가를 배경으로, 중추신경계 및 말초신경계 질환을 대상으로 한 치료제, 진단법, 의료기기의 연구 개발이 활발히 이루어지고 있는 분야입니다. 아밀로이드를 표적으로 하는 약물의 도입은 임상시험 활동을 크게 활성화시켰으며, 한편 ‘브레이크스루 테라피’ 지정을 포함한 규제상의 우대 조치 덕분에 피험자 모집과 자금 조달이 신속하게 이루어졌습니다. 현재, 이처럼 확대되고 있는 치료 환경을 활용하기 위해 많은 후원사, 스타트업 기업 및 컨소시엄이 시장에 진출하고 있습니다. 또한, 바이오마커와 혁신적인 연구 설계의 도입으로 피험자 모집의 효율성이 높아지고 데이터 수집이 개선되었으며, 웨어러블 센서와 모바일 애플리케이션을 통해 질환의 진행 상황을 실시간으로 추적할 수 있게 되었습니다. 규제 당국의 지지를 바탕으로 한 이러한 성장 궤도를 통해, 시장은 맞춤형 치료 및 임상시험 네트워크의 추가적인 발전을 위한 기반을 마련하고 있습니다.
세계 신경학 임상시험 시장의 성장요인
알츠하이머병, 파킨슨병, 다발성 경화증, 간질 등의 신경 질환 유병률 증가가 혁신적인 치료법에 대한 수요를 촉진하고 있으며, 이는 임상시험의 증가로 이어지고 있습니다. 환자 수가 증가함에 따라 피험자 등록이 용이해졌고, 그 결과 연구 인프라에 대한 투자가 촉진되며, 학술 기관, 계약 연구 기관(CRO), 제약 회사 간의 파트너십이 형성되고 있습니다. 이러한 협력적인 분위기는 개발 파이프라인을 강화하고, 전 세계 신경학 임상시험 시장의 지속적인 성장을 이끌고 있습니다. 또한, 다양한 지역에 걸친 다기관 공동 연구를 통해 질환의 진행 메커니즘에 대한 과학적 이해가 깊어지고, 규제 대응 능력도 높아지고 있습니다.
세계 신경학 임상시험 시장의 제약요인
세계 신경학 임상시험 시장은 신경계 치료의 안전성과 유효성을 확보하기 위한 엄격한 규제 요건으로 인해 큰 과제에 직면해 있습니다. 이러한 기준에 따라 광범위한 전임상 데이터, 장기간에 걸친 추적 관찰 기간, 그리고 평가 지표에 대한 철저한 검증이 요구되며, 이로 인해 임상시험 설계가 복잡해지고 심사 기간이 길어지고 있습니다. 그 결과, 스폰서는 더 많은 자원을 투입하고, 보다 보수적인 개발 방식을 채택할 수밖에 없게 되었습니다. 이러한 상황은 신규 시험의 시작을 지연시키고 시장 성장을 저해할 뿐만 아니라, 이처럼 강화된 규정 준수 기준을 충족하는 데 어려움을 겪을 가능성이 있는 중소기업들의 활동을 위축시키고 있습니다. 그 결과, 시험 운영은 종종 대규모 다국적 기업에 집중되어 경쟁이 더욱 제한되게 됩니다.
세계 신경학 임상시험 시장의 동향
세계 신경학 임상시험 시장은 신경약학의 혁신에 힘입어 획기적인 변화를 겪고 있습니다. 유전자 편집 치료, 생물학적 제제 및 정밀 의학의 통합으로 인해 임상시험의 연구 방법이 재정의되고 있으며, 후원사는 조기 결과 확보 및 바이오마커에 기반한 코호트 확대를 목적으로 적응형 프로토콜을 채택하고 있습니다. 이러한 진화를 통해 생명공학 기업과 학술 기관 간의 협력이 강화되어, 첨단 플랫폼에 대한 접근성과 희귀 신경 질환을 앓고 있는 틈새 환자 집단에 대한 접근성이 향상되고 있습니다. 그 결과, 시장은 더욱 유연하고 과학 중심적인 환경으로 진화하고 있으며, 기존의 광범위한 피험자 모집보다 타겟을 좁힌 접근 방식을 우선시하는 한편, 국제 시장의 규제 환경도 개선되어 궁극적으로 성공 가능성을 높이고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 신경학 분야 임상시험 시장 규모 : 단계별
세계의 신경학 분야 임상시험 시장 규모 : 연구 디자인별
세계의 신경학 분야 임상시험 시장 규모 : 적응증별
세계의 신경학 분야 임상시험 시장 규모 : 스폰서별
세계의 신경학 분야 임상시험 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.07.23Global Neurology Clinical Trials Market size was valued at USD 5.22 Billion in 2024 and is poised to grow from USD 5.55 Billion in 2025 to USD 9.11 Billion by 2033, growing at a CAGR of 6.39% during the forecast period (2026-2033).
The global neurology clinical trials market represents a dynamic arena for investigating therapeutics, diagnostics, and devices targeting central and peripheral nervous system disorders, driven by rising incidences of neurodegenerative diseases such as Alzheimer's and Parkinson's. The introduction of amyloid-targeting agents significantly stimulated trial activity, while regulatory incentives, including Breakthrough Therapy designations, facilitated faster enrollment and funding. An influx of sponsors, startups, and consortia now seek to capitalize on this expanding therapeutic landscape. Additionally, the integration of biomarkers and innovative trial designs enhances recruitment efficiency and data collection, with wearable sensors and mobile applications enabling real-time tracking of disease progression. This growth trajectory, supported by regulatory endorsements, positions the market for further advancements in personalized therapeutics and trial networks.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Neurology Clinical Trials market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Neurology Clinical Trials Market Segments Analysis
Global neurology clinical trials market is segmented by phase, study design, indication, sponsor and region. Based on phase, the market is segmented into Phase I, Phase II, Phase III and Phase IV (Post-Marketing). Based on study design, the market is segmented into Interventional Studies and Observational Studies. Based on indication, the market is segmented into Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Epilepsy, ALS (Amyotrophic Lateral Sclerosis), Stroke and Other CNS Disorders. Based on sponsor, the market is segmented into Pharmaceutical & Biotech Companies, Academia & Research Institutes and Government Agencies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Neurology Clinical Trials Market
The rising prevalence of neurological disorders like Alzheimer's disease, Parkinson's disease, multiple sclerosis, and epilepsy is fueling the demand for innovative treatment options, leading to an increase in clinical trials. As the patient population grows, enrolling participants becomes easier, which in turn promotes investment in research infrastructure and fosters partnerships among academic institutions, contract research organizations, and pharmaceutical companies. This collaborative atmosphere enhances the development pipeline, driving sustained growth in the global neurology clinical trials market. Additionally, it deepens the scientific understanding of disease processes and encourages regulatory adaptability through multi-center collaborations across various regions.
Restraints in the Global Neurology Clinical Trials Market
The Global Neurology Clinical Trials market faces significant challenges due to stringent regulatory requirements aimed at ensuring safety and efficacy in neurological therapies. These standards necessitate extensive pre-clinical data, prolonged follow-up periods, and thorough validation of endpoints, which complicate trial designs and extend review periods. As a result, sponsors are compelled to dedicate more resources and adopt more conservative development approaches. This situation leads to a slowdown in the initiation of new trials, hindering market growth and discouraging smaller companies that may struggle to meet these heightened compliance standards. Consequently, trial operations often consolidate within larger multinational firms, further restricting competition.
Market Trends of the Global Neurology Clinical Trials Market
The Global Neurology Clinical Trials market is undergoing a transformative shift propelled by neuropharmaceutical innovation. The integration of gene-editing therapies, biologics, and precision medicine is redefining trial methodologies, with sponsors embracing adaptive protocols for early insights and biomarker-driven cohort expansions. This evolution is fostering increased collaboration between biotech firms and academic institutions, enhancing access to advanced platforms and niche patient populations with rare neurological conditions. As a result, the market is evolving into a more agile, science-oriented landscape, prioritizing targeted approaches over traditional broad enrollment, while also improving regulatory alignment across international markets, ultimately increasing the likelihood of successful outcomes.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Neurology Clinical Trials Market Size by Phase & CAGR (2026-2033)
- Market Overview
- Phase I
- Phase II
- Phase III
- Phase IV (Post-Marketing)
Global Neurology Clinical Trials Market Size by Study Design & CAGR (2026-2033)
- Market Overview
- Interventional Studies
- Observational Studies
Global Neurology Clinical Trials Market Size by Indication & CAGR (2026-2033)
- Market Overview
- Alzheimer's Disease
- Parkinson's Disease
- Multiple Sclerosis
- Epilepsy
- ALS (Amyotrophic Lateral Sclerosis)
- Stroke
- Other CNS Disorders
Global Neurology Clinical Trials Market Size by Sponsor & CAGR (2026-2033)
- Market Overview
- Pharmaceutical & Biotech Companies
- Academia & Research Institutes
- Government Agencies
Global Neurology Clinical Trials Market Size & CAGR (2026-2033)
- North America (Phase, Study Design, Indication, Sponsor)
- US
- Canada
- Europe (Phase, Study Design, Indication, Sponsor)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Phase, Study Design, Indication, Sponsor)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Phase, Study Design, Indication, Sponsor)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Phase, Study Design, Indication, Sponsor)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- IQVIA Holdings Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Covance (Labcorp Drug Development)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Charles River Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Medpace Holdings
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Syneos Health
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Icon plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PARENTEXEL International
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PPD (Thermo Fisher Scientific)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novatek International
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- International SOS
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biogen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche Holding AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson (Janssen)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alector LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Denali Therapeutics Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
